BioMarin Exec Gregory Friberg Buys 19,150 Shares Amid RSU Grant — A Quiet Signal of Confidence in the Biotech Company’s Pipeline

Insider Activity at BioMarin: What the Latest Deal Means

BioMarin’s recent filing shows EVP & Chief R&D Officer Gregory Friberg buying 19,150 shares of common stock on March 16, 2026, the same day the company granted restricted stock units. The trade was executed at the market price of $55.46, just a hair above the close of $56.05.

Implications for the Share Price and Investor Sentiment The purchase of a sizable block of shares by a senior executive typically signals confidence in the company’s trajectory. Friberg’s buy is consistent with a long‑term view: his current holding jumps to 56,728 shares—an increase of roughly 16 % from the 46,035 shares reported a month earlier. Meanwhile, the broader insider activity shows mixed buying and selling, but the net effect is a modest net purchase across the board. In a market where BioMarin’s share price has been sliding—down 8.2 % weekly, 7.6 % monthly, and 22.7 % over the year—Friberg’s commitment can serve as a quiet rallying point for shareholders. The market‑impact of a single transaction of this size is small relative to the company’s $11 billion market cap, but the signal may help curb some of the bearish momentum.

What Investors Should Watch

1. Timing of the Restricted Stock Units – The RSUs granted on March 16 have no immediate cash flow impact, but they will vest in 2027, potentially creating a future supply of shares that could influence liquidity.
2. Option Grants – Friberg also purchased 45,600 stock options, set to vest monthly starting March 2027. This aligns his interests with long‑term value creation, but it also hints at the company’s confidence in a future price appreciation that would make exercising profitable.
3. Peer Comparisons – Other executives (e.g., Chief Commercial Officer Cristin, Chief Technical Officer Greg Guyer, and CFO Mueller) are also buying shares, suggesting a corporate consensus that the company is undervalued relative to its pipeline.

Friberg Gregory R: A Profile Through Past Transactions Friberg’s trading history shows a pattern of disciplined buying and selling that reflects a strategic approach. Over the past year he has:

• Sold 6,326 shares in February 2026 at $60.38, a price above the March close, indicating a short‑term divestment while maintaining a substantial holding.
• Bought 398 shares in October 2025 at $45.54, the lowest price in the data set, suggesting opportunistic purchases when the market dips.
• Sold 3,304 shares in September 2025 at $54.16, again following a slight decline.

Overall, his net position has grown from 37,578 shares in February to 56,728 shares today—a net increase of 19,150 shares. The consistency of his trades—buys when the stock is below his average cost and sells at a modest premium—indicates a patient, long‑term view that aligns with BioMarin’s R&D‑heavy business model.

Looking Ahead The company’s pipeline of enzyme therapies for lysosomal storage diseases and burn treatments remains the primary driver of future value. Friberg’s recent purchases suggest that the company’s leadership is confident that these products will translate into revenue growth and, ultimately, a higher stock price. For investors, the insider buying activity should be viewed as a positive, albeit modest, signal of internal confidence in a company that has faced recent share price volatility.